TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
MicroPort CardioFlow Medtech Corp. ( (HK:2160) ) has provided an update.
MicroPort CardioFlow Medtech Corp. has announced the CE Mark approval of their AnchorMan® LAAC and LAAA Systems, which are designed for the closure of the left atrial appendage to prevent thrombus embolization. This approval marks a significant milestone for the company, as it not only validates their innovative design and clinical performance at an international level but also opens doors for expansion into the European market. This development is expected to enhance the company’s global competitiveness and provide more opportunities to serve patients with structural heart disease.
More about MicroPort CardioFlow Medtech Corp.
MicroPort CardioFlow Medtech Corp., based in the Cayman Islands, specializes in developing medical devices for structural heart disease treatment, with a focus on innovative research and development.
YTD Price Performance: 36.76%
Average Trading Volume: 1,084,746
Technical Sentiment Consensus Rating: Hold
Current Market Cap: HK$2.24B
Learn more about 2160 stock on TipRanks’ Stock Analysis page.